Downregulation of Tie2 gene by a novel antitumor sulfolipid, 3′-sulfoquinovosyl-1′-monoacylglycerol, targeting angiogenesis

Cancer Science

Volumn 99, Issue 5, 2008, Pages 1063-1070

  Mori, Yoko ^a   Sahara, Hiroeki ^a   Matsumoto, Kayo ^a   Takahashi, Nobuaki ^a   Yamazaki, Takayuki ^b   Ohta, Keisuke ^b   Aoki, Satoko ^b   Miura, Masahiko ^c   Sugawara, Fumio ^b   Sakaguchi, Kengo ^b   Sato, Noriyuki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3' SULFOQUINOVOSYL 1' MONOACYLGLYCEROL; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; VASCULOTROPIN; 1 MONO O ACYL 3 O (ALPHA D SULFOQUINOVOSYL) GLYCERIDE; 1-MONO-O-ACYL-3-O-(ALPHA-D-SULFOQUINOVOSYL)-GLYCERIDE; ANGIOGENESIS INHIBITOR; GLYCOLIPID; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; DRUG TARGETING; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR; STRUCTURE ANALYSIS; TUMOR CELL LINE; DOSE RESPONSE; ENZYMOLOGY; GENETICS; MALE; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; GLYCOLIPIDS; HUMANS; MALE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; RECEPTOR, TIE-2;

EID: 43649085218     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00785.x     Document Type: Article

References (42)

1. Folkman J. What is the evidence that tumor are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
2. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-6.
3. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
4. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
5. Fong TA, Shawver LK, Sun L et al. SU5416 is a potentand selective inhibitor of vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99-106.
6. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
7. Hurwitz H, Feherenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
8. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinicals studies. Cancer Res 2005; 65: 671-80.
9. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-74.
10. Eklund L, Olsen BR. Tie receptors and their angiopoietin ligands are context-depedent regulators of vascular remodeling. Exp Cell Res 2006; 312: 630-41.
11. Lin P, Polverini P, Dewhirst M, Shan S, Roao PS, Peters KG. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie-2 in pathologic vascular growth. J Clin Invest 1997; 100: 2072-8.
12. Lin P, Buxton JA, Acheson A et al. Anti-angiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA 1998; 95: 8829-34.
13. Siemeister G, Schirner M, Weindel K et al. Two independent mechanisms essential for tumor angiogenesis: Inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res 1999; 59: 3185-91.
14. Stratmann A, Acker T, Burger AM, Amann K, Risau W, Plate KH. Differential inhibition of tumor angiogenesis by Tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants. Int J Cancer 2001; 91: 273-82.
15. Hayes AJ, Huang WQ, Mallah J, Yang D, Lippman ME, Li LY. Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc Res 1999; 58: 224-37.
16. White RR, Shan S, Rusconi CP et al. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin. Proc Natl Acad Sci USA 2003; 100: 5028-33.
17. Niu Q, Perruzzi C, Voskas D, Lawler J, Dumont DJ, Benjamin LE. Inhibition of Tie-2 signaling induces endothelial cell apoptosis, decreases Akt signaling, and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1. Cancer Biol Ther 2004; 3: 402-5.
18. Tournaire R, Simon M-P, le Noble F, Eichmann A, England P, Pouyssegur J. A short synthetic peptide inhibits signal transduction, migration and angiogenesis mediated by Tie2 receptor. EMBO Rep 2004; 5: 1-6.
19. Sahara H, Ishikawa M, Takahashi N et al. In vivo anti-tumour effect of 3′-sulphonoquinovosyl 1′-monoacylglyceride isolated from sea urchin (Strongylocentrotus intermedius) intestine. Br J Cancer 1997; 75: 324-32.
20. Sahara H, Hanashima S, Yamazaki T et al. Anti-tumor effect of chemically synthesized sulfolipids based on sea urchin's natural sulfonoquinovosylmonoacylglycerols. Jpn J Cancer Res 2002; 93: 85-92.
21. Sakimoto I, Ohta K, Yamazaki T et al. α-Sulfoquinovosylmonoacylglycerol is a novel potent radiosensitizer targeting tumor angiogenesis. Cancer Res 2006; 66: 2287-95.
22. Solway J, Seltzer J, Samaha FF et al. Structure and expression of a smooth muscle cell-specific gene, SM22α. J Biol Chem 1995; 270: 13.460-9.
23. Zhang L, Yang N, Park J et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003; 63: 3403-12.
24. Yamori T, Matsunaga A, Sato S et al. Potent antitumor activity of MS-247, a novel DNA minor grove binder, evaluated by an in.vitro and in vivo human cancer cell line panel. Cancer Res 1999; 59: 4042-9.
25. Dan S, Tsunoda T, Kitahara O et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 2002; 62: 1139-47.
26. Dumont DJ, Yamaguchi TP, Conlon RA, Rossant J, Breitman ML. Tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in the endothelial cells and their presumptive precursors. Oncogene 1992; 7: 1471-80.
27. Dumont DJ, Gradwohl GJ, Fong GH, Auerbach R, Breitman ML. The endothelial-specific receptor tyrosine kinase, tek, is a member of a new subfamily of receptors. Oncogene 1993; 8: 1293-301.
28. Dumont DJ, Gradwohl G, Fong GH et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 1994; 8: 1897-909.
29. Sato TN, Tozawa Y, Deutsch U et al. Distinct roles of the receptor tyrosine kinases Tie1 and Tie-2 in blood vessel formation. Nature 1995; 376: 70-4.
30. Maisonpierre PC, Suri C, Jones PF et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science1997; 277: 55-60.
31. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997; 277: 48-50.
32. Davis S, Yancopoulos GD. The angiopoietins: Ying and yang in angiogenesis. Curr Top Microbiol Immunol 1999; 237: 173-85.
33. Hamaguchi I, Morisada T, Azuma M et al. Loss of Tie2 receptor compromises embryonic stem cell-derived endothelial but not hematopoitic cell survival. Blood 2006; 107: 1207-13.
34. Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 1997; 81: 567-74.
35. Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM. Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem 1998; 273: 18.514-21.
36. Koblizek TI, Weiss C, Yancopoulos GD, Deutsch U, Risau W. Angiopoietin-1 induces sprouting angiogenesis in.vitro. Curr Biol 1998; 8: 529-32.
37. Kim I, Kim HG, Moon SO et al. Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion. Circ Res 2000; 86: 952-9.
38. Kim I, Kim HG, So JN, Kim JH, Kwak HJ, Koh GY. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3V-kinase/Akt signal transduction pathway. Circ Res 2000; 86: 24-9.
39. Daly C, Wong V, Burova E et al. Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev 2004; 18: 1060-71.
40. Davis S, Aldrich TH, Jones PF et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161-9.
41. Hawighorst T, Skobe M, Streit M et al. Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 2002; 160: 1381-92.
42. Stoeltzing O, Ahmad SA, Liu W et al. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 2003; 63: 3370-7.